Nothing Special   »   [go: up one dir, main page]

NO20082345L - Selektive VPAC2 reseptorpeptidagonister - Google Patents

Selektive VPAC2 reseptorpeptidagonister

Info

Publication number
NO20082345L
NO20082345L NO20082345A NO20082345A NO20082345L NO 20082345 L NO20082345 L NO 20082345L NO 20082345 A NO20082345 A NO 20082345A NO 20082345 A NO20082345 A NO 20082345A NO 20082345 L NO20082345 L NO 20082345L
Authority
NO
Norway
Prior art keywords
vpac2 receptor
receptor peptide
peptide agonists
selective vpac2
selective
Prior art date
Application number
NO20082345A
Other languages
English (en)
Inventor
Lianshan Zhang
Bengt Krister Bokvist
Jorge Alsina-Fernandez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20082345L publication Critical patent/NO20082345L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)
  • Conductive Materials (AREA)
  • Harvester Elements (AREA)

Abstract

Den foreliggende oppfinnelsen omslutter peptider som selektivt aktiverer VPAC2 reseptoren og er nyttige i behandlingen av diabetes.
NO20082345A 2005-10-26 2008-05-23 Selektive VPAC2 reseptorpeptidagonister NO20082345L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73029105P 2005-10-26 2005-10-26
US74034205P 2005-11-29 2005-11-29
US74336406P 2006-02-28 2006-02-28
PCT/US2006/041550 WO2007050651A1 (en) 2005-10-26 2006-10-24 Selective vpac2 receptor peptide agonists

Publications (1)

Publication Number Publication Date
NO20082345L true NO20082345L (no) 2008-05-23

Family

ID=37716005

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082345A NO20082345L (no) 2005-10-26 2008-05-23 Selektive VPAC2 reseptorpeptidagonister

Country Status (12)

Country Link
US (2) US7582608B2 (no)
EP (1) EP1942941A1 (no)
JP (1) JP2009519212A (no)
KR (1) KR101057284B1 (no)
CN (1) CN101296708B (no)
AU (1) AU2006306236B2 (no)
BR (1) BRPI0617740A2 (no)
CA (1) CA2627716A1 (no)
EA (1) EA012930B1 (no)
IL (1) IL189922A0 (no)
NO (1) NO20082345L (no)
WO (1) WO2007050651A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10328316A1 (de) 2003-06-23 2005-01-20 Grünenthal GmbH Verfahren zur Herstellung von Dimethyl-(3-aryl-buthyl)-aminverbindungen als pharmazeutische Wirkstoffe
EP1781694A1 (en) * 2004-08-18 2007-05-09 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20090170775A1 (en) * 2004-10-08 2009-07-02 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide compositions
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
DE102005052588A1 (de) * 2005-11-02 2007-05-10 Grünenthal GmbH Verfahren zur Herstellung substituierter Dimethyl-(3-aryl-butyl)-amin-Verbindungen mittels homogener Katalyse
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
TWI496762B (zh) 2006-07-24 2015-08-21 製備（１ｒ，２ｒ）-３-（３-二甲胺基-１-乙基-２-甲基-丙基）-酚之方法
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
EP2464370B1 (en) * 2009-08-14 2017-03-29 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
CN114652817A (zh) 2015-02-09 2022-06-24 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04193896A (ja) * 1989-10-26 1992-07-13 Meiji Seika Kaisha Ltd 活性ペプチド
JPH0692991A (ja) 1991-02-28 1994-04-05 Daicel Chem Ind Ltd 新規活性ペプチド
WO1998002453A2 (en) 1996-07-15 1998-01-22 Universite Libre De Bruxelles Peptidic ligands having a higher selectivity for the vip1 receptor than for the vip2 receptor
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
ATE449789T1 (de) 1998-07-20 2009-12-15 Ipsen Pharma Pacap-peptidanaloga
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
BR0010705A (pt) 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Exendinas modificadas e agonistas da exendina
HUP0202175A3 (en) 1999-09-28 2005-01-28 Bayer Corp Berkeley Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
BR0306706A (pt) 2002-01-08 2007-03-27 Lilly Co Eli peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica
EP1578358A2 (en) 2002-07-12 2005-09-28 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
WO2004093823A2 (en) * 2003-03-19 2004-11-04 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
BRPI0417717A (pt) * 2003-12-18 2007-04-03 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
RU2006130691A (ru) * 2004-01-27 2008-03-10 Байер Фармасьютикалс Корпорейшн (US) Агонисты рецептора (vpac2), активирующего аденилатциклазу гипофиза пептида (расар), и фармакологические способы их применения
WO2005113593A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
EP1756156B1 (en) * 2004-05-21 2008-10-22 Eli Lilly And Company Selective vpac2 receptor peptide agonists
EP1781694A1 (en) * 2004-08-18 2007-05-09 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US7595294B2 (en) 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
MX2007004116A (es) 2004-10-08 2007-10-05 Forbes Medi Tech Res Inc Composiciones farmaceuticas de polipeptidos intestinales vasoactivos.

Also Published As

Publication number Publication date
AU2006306236A1 (en) 2007-05-03
CN101296708A (zh) 2008-10-29
US20100009916A1 (en) 2010-01-14
US20080234198A1 (en) 2008-09-25
IL189922A0 (en) 2008-08-07
CA2627716A1 (en) 2007-05-03
KR20080053393A (ko) 2008-06-12
CN101296708B (zh) 2011-12-07
US7582608B2 (en) 2009-09-01
EA012930B1 (ru) 2010-02-26
AU2006306236B2 (en) 2011-12-01
US7897573B2 (en) 2011-03-01
EA200801180A1 (ru) 2008-08-29
KR101057284B1 (ko) 2011-08-16
JP2009519212A (ja) 2009-05-14
WO2007050651A1 (en) 2007-05-03
BRPI0617740A2 (pt) 2011-08-02
EP1942941A1 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
NL301089I2 (nl) imlifidase
DOP2006000025A (es) Agonistas de pyy y sus usos
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
EA200701918A1 (ru) Белок липокалин
GB2430677A8 (en) Novel antigenbinding polypeptides and their uses
CY1115004T1 (el) Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
MXPA06003474A (es) Agonistas de receptores de melanocortina.
DK2068909T3 (da) Modificerede FGF-21-polypeptider og anvendelse heraf
EA200600055A1 (ru) Агонисты рецептора меланокортина 4 (мк4 ) и их применение
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MXPA06011924A (es) Dispositivo de liberacion continua base polimeros.
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
MX2009010148A (es) Peptidos ciclicos de proteinas receptor-asociadas (rap).
WO2007101146A3 (en) Selective vpac2 receptor peptide agonists
WO2007133828A3 (en) Selective vpac2 receptor peptide agonists
EA200702193A1 (ru) Гликозилирование белков
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
CY1114618T1 (el) Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη
EP1978994A4 (en) BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
WO2006023356A3 (en) Selective vpac2 receptor peptide agonists
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application